{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:18:01Z","timestamp":1648736281138},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00292-018-0520-0","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T04:32:12Z","timestamp":1540182732000},"page":"199-207","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protein-Dysregulationen in humanen und murinen myeloproliferativen Neoplasien"],"prefix":"10.1007","volume":"39","author":[{"given":"K.","family":"Aumann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"key":"520_CR1","first-page":"696","volume-title":"Diagnostic surg. pathol","author":"S Kroft","year":"2015","unstructured":"Kroft S, Harrington A et\u00a0al (2015) Bone marrow \u2013 myeloproliferative neoplasms. In: Mills S, Greenson J, Hornick J, Longacre T, Reuter V (Hrsg) Diagnostic surg. pathol, 6.\u00a0Aufl. Wolters Kluwer, Dordrecht, S\u00a0696\u2013702","edition":"6"},{"key":"520_CR2","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Campo, Harris, Jaffe, Pileri, Stein (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization, International Agency for Research on Cancer"},{"key":"520_CR3","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1158\/0008-5472.CAN-08-4252","volume":"69","author":"M Buchner","year":"2009","unstructured":"Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholom\u00e9 K, Burger M et\u00a0al (2009) Spleen tyrosine kinase is overexpressed and represents a\u00a0potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 69:5424\u20135432. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4252","journal-title":"Cancer Res"},{"key":"520_CR4","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.1158\/0008-5472.CAN-08-3719","volume":"70","author":"C Dierks","year":"2010","unstructured":"Dierks C, Adrian F, Fisch P, Ma H, Maurer H, Herchenbach D et al (2010) The ITK-SYK fusion oncogene induces a\u00a0T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res 70:6193\u20136204. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3719","journal-title":"Cancer Res"},{"key":"520_CR5","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1046\/j.1365-2141.1999.01607.x","volume":"106","author":"Y Kuno","year":"1999","unstructured":"Kuno Y, Abe A, Emi N, Iida M, Yamamori T, Tanimoto M et\u00a0al (1999) An atypical myelodysplastic syndrome with t(9;12)(q22;p12) and TEL gene rearrangement. Br J Haematol 106:570\u2013571. \n                    https:\/\/doi.org\/10.1046\/j.1365-2141.1999.01607.x","journal-title":"Br J Haematol"},{"key":"520_CR6","volume-title":"Die Rolle von SYK in h\u00e4matologischen Erkrankungen","author":"C Sprissler","year":"2013","unstructured":"Sprissler C (2013) Die Rolle von SYK in h\u00e4matologischen Erkrankungen. Fakult\u00e4t f\u00fcr Biologie. Albert Ludwigs-Universit\u00e4t Freiburg, Breisgau"},{"issue":"4","key":"520_CR7","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1038\/bcj.2014.53","volume":"22","author":"C Sprissler","year":"2014","unstructured":"Sprissler C, Belenki D, Maurer H, Aumann K, Pfeifer D, Klein C, M\u00fcller TA, Kissel S, H\u00fclsd\u00fcnker J, Alexandrovski J, Brummer T, Jumaa H, Duyster J, Dierks C (2014) Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice. Blood Cancer J 22(4):e240. \n                    https:\/\/doi.org\/10.1038\/bcj.2014.53","journal-title":"Blood Cancer J"},{"key":"520_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.V100.1.238","volume":"100","author":"SC Kogan","year":"2002","unstructured":"Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD et\u00a0al (2002) Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100:238\u2013245","journal-title":"Blood"},{"key":"520_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et\u00a0al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809\u20131820. \n                    https:\/\/doi.org\/10.1182\/blood-2006-02-005686","journal-title":"Blood"},{"key":"520_CR10","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et\u00a0al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J\u00a0Clin Oncol 27:6041\u20136051. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.25.0779","journal-title":"J Clin Oncol"},{"key":"520_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garc\u00eda-Guti\u00e9rrez V, Hochhaus A et al (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. \n                    https:\/\/doi.org\/10.1038\/leu.2016.104","journal-title":"Leukemia"},{"key":"520_CR12","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a\u00a0therapeutic agent for chronic myeloid leukemia. Blood 105:2640\u20132653. \n                    https:\/\/doi.org\/10.1182\/blood-2004-08-3097","journal-title":"Blood"},{"key":"520_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172\u2013183. \n                    https:\/\/doi.org\/10.1038\/nrc1567","journal-title":"Nat Rev Cancer"},{"key":"520_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","volume":"1","author":"M Sattler","year":"2002","unstructured":"Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et\u00a0al (2002) Critical role for Gab2 in transformation by BCR\/ABL. Cancer Cell 1:479\u2013492","journal-title":"Cancer Cell"},{"key":"520_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1478-811X-7-22","volume":"7","author":"FU Wohrle","year":"2009","unstructured":"Wohrle FU, Daly RJ, Brummer T (2009) Function, regulation and pathological roles of the Gab\/DOS docking proteins. Cell Commun Signal 7:22. \n                    https:\/\/doi.org\/10.1186\/1478-811X-7-22","journal-title":"Cell Commun Signal"},{"key":"520_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","volume":"105","author":"S Koschmieder","year":"2005","unstructured":"Koschmieder S, G\u00f6ttgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL et al (2005) Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a\u00a0transgenic model of BCR-ABL leukemogenesis. Blood 105:324\u2013334. \n                    https:\/\/doi.org\/10.1182\/blood-2003-12-4369","journal-title":"Blood"},{"key":"520_CR17","volume-title":"Gab2 and its role in tyrosine kinase inhibitor resistance in chronic myeloid leukemia","author":"S Halbach","year":"2016","unstructured":"Halbach S (2016) Gab2 and its role in tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Fakult\u00e4t f\u00fcr Biologie. Albert-Ludwigs-Universit\u00e4t, Freiburg"},{"issue":"9","key":"520_CR18","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1038\/leu.2016.92","volume":"30","author":"S Halbach","year":"2016","unstructured":"Halbach S, K\u00f6hler M, Uhl FM, Huber J, Zeiser R, Koschmieder S, Aumann K,  Brummer T (2016) Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model. Leukemia 30 (9):1942\u20131945","journal-title":"Leukemia"},{"key":"520_CR19","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood.V99.5.1866","volume":"99","author":"K Nishida","year":"2002","unstructured":"Nishida K, Wang L, Morii E, Park SJ, Narimatsu M, Itoh S et al (2002) Requirement of Gab2 for mast cell development and KitL\/c-Kit signaling. Blood 99:1866\u20131869","journal-title":"Blood"},{"key":"520_CR20","doi-asserted-by":"publisher","first-page":"9967","DOI":"10.1158\/0008-5472.CAN-06-1346","volume":"66","author":"K Kometani","year":"2006","unstructured":"Kometani K, Aoki M, Kawamata S, Shinozuka Y, Era T, Taniwaki M et al (2006) Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a\u00a0mouse model. Cancer Res 66:9967\u20139976. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1346","journal-title":"Cancer Res"},{"key":"520_CR21","doi-asserted-by":"publisher","first-page":"16421","DOI":"10.1074\/jbc.272.26.16421","volume":"272","author":"H Gu","year":"1997","unstructured":"Gu H, Griffin JD, Neel BG (1997) Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells. J\u00a0Biol Chem 272:16421\u201316430","journal-title":"J Biol Chem"},{"key":"520_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1097-2765(00)80288-9","volume":"2","author":"H Gu","year":"1998","unstructured":"Gu H, Pratt JC, Burakoff SJ, Neel BG (1998) Cloning of p97\/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a\u00a0novel pathway for cytokine-induced gene activation. Mol Cell 2:729\u2013740","journal-title":"Mol Cell"},{"key":"520_CR23","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1182\/blood-2005-08-3087","volume":"107","author":"M Scherr","year":"2006","unstructured":"Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, Ganser A et\u00a0al (2006) Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 107:3279\u20133287. \n                    https:\/\/doi.org\/10.1182\/blood-2005-08-3087","journal-title":"Blood"},{"issue":"5","key":"520_CR24","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.humpath.2010.09.012","volume":"42","author":"K Aumann","year":"2011","unstructured":"Aumann K, Lassmann S, Sch\u00f6pflin A, May AM, W\u00f6hrle FU, Zeiser R et al (2011) The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia. Human Pathology 42(5):719\u2013726","journal-title":"Human Pathology"},{"key":"520_CR25","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1128\/MCB.19.3.1784","volume":"19","author":"CR Maroun","year":"1999","unstructured":"Maroun CR, Holgado-Madruga M, Royal I, Naujokas MA, Fournier TM, Wong AJ et al (1999) The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 19:1784\u20131799","journal-title":"Mol Cell Biol"},{"key":"520_CR26","volume-title":"Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors","author":"FU W\u00f6hrle","year":"2012","unstructured":"W\u00f6hrle FU (2012) Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Albert Ludwigs-Universit\u00e4t, Freiburg, Breisgau"},{"key":"520_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/leu.2012.222","volume":"27","author":"F U W\u00f6hrle","year":"2013","unstructured":"W\u00f6hrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, La\u00dfmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T (2013) Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Leukemia 27(1):118\u2013129","journal-title":"Leukemia"},{"key":"520_CR28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/367568a0","volume":"367","author":"K Igarashi","year":"1994","unstructured":"Igarashi K, Kataoka K, Itoh K, Hayashi N, Nishizawa M, Yamamoto M (1994) Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins. Nature 367:568\u2013572. \n                    https:\/\/doi.org\/10.1038\/367568a0","journal-title":"Nature"},{"key":"520_CR29","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/362722a0","volume":"362","author":"NC Andrews","year":"1993","unstructured":"Andrews NC, Erdjument-Bromage H, Davidson MB, Tempst P, Orkin SH (1993) Erythroid transcription factor NF-E2 is a\u00a0haematopoietic-specific basic-leucine zipper protein. Nature 362:722\u2013728. \n                    https:\/\/doi.org\/10.1038\/362722a0","journal-title":"Nature"},{"key":"520_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1182\/blood-2012-11-463257","volume":"122","author":"K. Aumann","year":"2013","unstructured":"Aumann K, Frey A\u2011V, May AM, Hauschke D, Kreutz C, Marx JP, Timmer J, Werner M, Pahl HL (2013) Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia. Blood 122 (1):93\u201399","journal-title":"Blood"},{"issue":"3","key":"520_CR31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2011.047811","volume":"97","author":"T Buhr","year":"2012","unstructured":"Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H et\u00a0al (2012) European bone marrow working group trial on reproducibility of world health organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 97(3):360\u2013365. \n                    https:\/\/doi.org\/10.3324\/haematol.2011.047811\n                    \n                   (comment)","journal-title":"Haematologica"},{"key":"520_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","volume":"111","author":"BS Wilkins","year":"2008","unstructured":"Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL et\u00a0al (2008) Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 111:60\u201370. \n                    https:\/\/doi.org\/10.1182\/blood-2007-05-091850","journal-title":"Blood"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-018-0520-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-018-0520-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-018-0520-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T20:04:36Z","timestamp":1571688276000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-018-0520-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":32,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["520"],"URL":"https:\/\/doi.org\/10.1007\/s00292-018-0520-0","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"assertion":[{"value":"22 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Aumann gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet vom Autor durchgef\u00fchrte Studien an Menschen und Tieren. Diese Studien wurden von der lokalen Ethikkomission bzw. dem Regierungspr\u00e4sidium genehmigt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}